About InVivoSIM anti-human CD38 (Daratumumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Daratumumab making it ideal for research use. The Daratumumab biosimilar antibody reacts with human CD38 a 42 kDa type II transmembrane glycoprotein. CD38 is expressed on immature and mature resting and activated B cells as well as NK cells and a subset of T cells. CD38 expression is down-regulated on mouse germinal center B cells and plasma cells. CD38 is a multifunctional protein involved in NAD homeostasis and in the generation of the second messengers ADPR and cyclic ADPR which are involved in intracellular calcium signaling. Antibodies against CD38 have been shown to be highly efficacious in the treatment of multiple myeloma. InVivoSIM anti-human CD38 (Daratumumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman CD38 Reported ApplicationsFunctional assays ELISA Western blot Flow cytometry FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
